Advances in Immunotherapy: Tackling CAR T-cell Therapy Resistance

In a study published in the AACR’s journal Cancer Discovery in December, a team of researchers from the Perelman School of Medicine and the Children’s Hospital of Philadelphia identified mechanisms by which some children’s B-cell leukemias develop resistance to CD19 CAR T-cell therapy, an investigational immunotherapy that yields long-lasting remissions in many patients with this disease.

Read More

New Type of Cancer Immunotherapeutic Approved by FDA: What It Means for Leukemia Patients

Earlier this month we witnessed another leap forward for immunotherapy when the FDA approved blinatumomab (Blincyto) for the treatment of certain patients with acute lymphoblastic leukemia (ALL).

Read More